Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis

Mengjiao Yang; Mengjiao Yang; Hao Yuan; Ya Zheng; Yuping Wang; Qinghong Guo; Mengjiao Yang; Hao Yuan; Ya Zheng; Yuping Wang; Qinghong Guo

Return

Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis

Author: Mengjiao YANG ¹ ; Mengjiao YANG ² ; Hao YUAN ² ; Ya ZHENG ² ; Yuping WANG ² ; Qinghong GUO ² ; Mengjiao YANG ³ ; Hao YUAN ³ ; Ya ZHENG ³ ; Yuping WANG ³ ; Qinghong GUO ³
Author Information

1. Lanzhou University, First Clinical Medical College
2. First Hospital of Lanzhou University, Department of Gastroenterology
3. Gansu Provincial Key Laboratory of Gastroenterology
Publication Type:Journal Article
Keywords: adverse reaction; clinical efficacy; mechanism of action; potassium-competitive acid blockers; reflux esophagitis
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(10):1190-1196
CountryChina
Language:Chinese
Abstract: Reflux Esophagitis (RE) is a gastroesophageal motility disorder mainly caused by lower esophageal sphincter disorder caused by a variety of injury factors, acid-suppressing drugs such as Proton Pump Inhibitors (PPIs) are often used clinically. With the increase of PPIs-resistant reflux esophagitis cases, the demand for the pharmacokinetics and pharmacodynamics of acid-suppressing drugs is higher. In recent years, the emergence of a new class of acid-suppressing drugs, potassium-competitive acid blockers (P-CABs), has solved some clinical deficiencies of traditional proton pump inhibitors. It has the characteristics of effective, longer-lasting acid suppression, the inhibitory effect on gastric acid secretion is not affected by the state of gastric acid secretion, the individual differences in drug metabolism and efficacy are smaller, and the drug efficacy is not affected by food intake or not. It has obvious advantages in the efficacy of severe erosive esophagitis and PPIs-resistant severe erosive esophagitis, and is more cost-effective, and is expected to replace PPI as the first-line treatment for reflux esophagitis.